Anzeige
Mehr »
Mittwoch, 16.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A140ML | ISIN: JE00BYSS4X48 | Ticker-Symbol: 038
Tradegate
15.07.25 | 13:40
15,250 Euro
+5,32 % +0,770
1-Jahres-Chart
NOVOCURE LIMITED Chart 1 Jahr
5-Tage-Chart
NOVOCURE LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
14,29014,65007:14
14,21514,64007:08

Aktuelle News zur NOVOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.07.NovoCure stock initiated with Buy rating at Ladenburg Thalmann1
08.07.Ladenburg Thalmann startet NovoCure-Aktie mit Kaufempfehlung3
03.07.NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data2
NOVOCURE Aktie jetzt für 0€ handeln
30.06.Novocure to Report Second Quarter 2025 Financial Results193Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast...
► Artikel lesen
27.06.Demystifying NovoCure: Insights From 4 Analyst Reviews3
06.06.NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial5
02.06.Novocure study shows improved pancreatic cancer survival9
02.06.NovoCure's Tumor Treating Fields Boosts One-Year And Pain-Free Survival In Pancreatic Cancer Trial3
02.06.H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data4
02.06.NovoCure Ltd - 8-K, Current Report1
01.06.Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Succeeds in Phase 3 Trial5
31.05.Zai Lab Limited: Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting822TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for...
► Artikel lesen
31.05.Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting463TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients...
► Artikel lesen
27.05.Novocure Announces Upcoming Investor Events266Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May...
► Artikel lesen
25.04.Why NovoCure Stock Skyrocketed This Week8
25.04.H.C. Wainwright maintains Buy on NovoCure, $38 price target9
25.04.Why NovoCure Stock Leaped 4% Higher Today4
24.04.NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 20253
24.04.Novocure outlines expansion plans for lung cancer treatment and regulatory milestones in 20253
24.04.Novocure Reports First Quarter 2025 Financial Results342Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as...
► Artikel lesen
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1